# Lexaria Bioscience Corp. (LEXX) — delisting [announced]
Source: SEC API (secapi.ai) · situation sit_38715575f4c8589066de · retrieved 2026-08-11T16:10:48.579Z

## Overview
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, operating the patented DehydraTECH technology which improves oral drug bioabsorption and reduces side effects; the company holds 66 granted patents and additional pending patents worldwide.

Lexaria Bioscience Corp. filed a Certificate of Change on July 29, 2026, authorizing a 1-for-15 reverse stock split of its common stock, effective August 3, 2026 at 12:01 a.m. Eastern Time. The reverse split will consolidate the Company's authorized shares from 220,000,000 to approximately 14,666,667 shares, and its outstanding shares from 24,787,446 to approximately 1,652,518 shares (subject to rounding adjustments). The primary purpose is to restore compliance with NASDAQ Capital Market's minimum $1.00 bid price requirement under Listing Rule 5550(a)(2), and secondarily to stabilize stock conditions and enhance the Company's ability to attract business development partners. No stockholder approval was required under Nevada law.

## Key dates
- Announced 2026-07-30

## Timeline
- 2026-07-30 · 8-K (0001640334-26-001258): 8-K - Lexaria Bioscience Corp. — *Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, operating the patented DehydraTECH technology which improves oral drug bioabsorption and reduces side effects; the company holds 66 granted patents and additional pending patents worldwide.* Lexaria Bioscience Corp. filed a Certificate of Change on July 29, 2026, authorizing a 1-for-15 reverse stock split of its common stock, effective August 3, 2026 at 12:01 a.m. Eastern Time. The reverse split will consolidate the Company's authorized shares from 220,000,000 to approximately 14,666,667 shares, and its outstanding shares from 24,787,446 to approximately 1,652,518 shares (subject to rounding adjustments). The primary purpose is to restore compliance with NASDAQ Capital Market's minimum $1.00 bid price requirement under Listing Rule 5550(a)(2), and secondarily to stabilize stock conditions and enhance the Company's ability to attract business development partners. No stockholder approval was required under Nevada law.
  https://www.sec.gov/Archives/edgar/data/1348362/0001640334-26-001258.txt

## Citations
- 0001640334-26-001258 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000164033426001258